Abstract

BackgroundFascin is an actin-bundling protein that is absent from most normal epithelia yet is upregulated in multiple forms of human carcinoma, where its expression correlates clinically with a poor prognosis. How fascin-1 transcription is activated in carcinoma cells is largely unknown, although the hypothesis of regulation by β-catenin signaling has received attention. The question is important because of the clinical significance of fascin expression in human carcinomas.Methodology/Principal FindingsThrough comparative genomics we made an unbiased analysis of the DNA sequence of the fascin-1 promoter region from six mammalian species. We identified two regions in which highly conserved motifs are concentrated. Luciferase promoter reporter assays for the human fascin-1 promoter were carried out in fascin-positive and -negative human breast and colon carcinoma cells, and in human dermal fibroblasts that are constitutively fascin-positive. In all fascin-positive cells, the region −219/+114 that contains multiple highly conserved motifs had strong transcriptional activity. The region −2953/−1582 appeared to contain repressor activity. By examining the effects of single or multiple point mutations of conserved motifs within the −219/+114 region on transcriptional reporter activity, we identified for the first time that the conserved CREB and AhR binding motifs are major determinants of transcriptional activity in human colon carcinoma cells. Chromatin immunoprecipitations for CREB, AhR or β-catenin from extracts from fascin-positive or -negative human colon carcinoma cells identified that CREB and AhR specifically associate with the −219/+114 region of the FSCN1 promoter in fascin-positive colon carcinoma cells. An association of β-catenin was not specific to fascin-positive cells.ConclusionUpregulation of fascin-1 in aggressive human carcinomas appears to have a multi-factorial basis. The data identify novel roles for CREB and AhR as major, specific regulators of FSCN-1 transcription in human carcinoma cells but do not support the hypothesis that β-catenin signaling has a central role.

Highlights

  • Abnormalities of the actin cytoskeleton make important contributions to the ability of carcinoma cells to invade adjacent tissue and metastasise via the blood or lymphatic systems to remote body sites [1]

  • Fascin is of considerable interest as a biomarker or potential therapeutic target because it is not expressed by simple epithelia and is low or absent in stratified epithelia, yet is strongly upregulated in most forms of human carcinoma [10,11,12,13,14,15]

  • In all forms of human carcinoma examined to date, high tumour expression of fascin protein is of clinical significance and is associated with a poor prognosis in carcinomas of the lung, oesophagus, stomach, colon, breast and kidney [5,11,12,14,15,16,17]

Read more

Summary

Introduction

Abnormalities of the actin cytoskeleton make important contributions to the ability of carcinoma cells to invade adjacent tissue and metastasise via the blood or lymphatic systems to remote body sites [1]. Fascin is of considerable interest as a biomarker or potential therapeutic target because it is not expressed by simple epithelia and is low or absent in stratified epithelia, yet is strongly upregulated in most forms of human carcinoma [10,11,12,13,14,15]. In all forms of human carcinoma examined to date, high tumour expression of fascin protein is of clinical significance and is associated with a poor prognosis in carcinomas of the lung, oesophagus, stomach, colon, breast and kidney [5,11,12,14,15,16,17]. Fascin is an actin-bundling protein that is absent from most normal epithelia yet is upregulated in multiple forms of human carcinoma, where its expression correlates clinically with a poor prognosis. The question is important because of the clinical significance of fascin expression in human carcinomas

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call